MiNK Therapeutics (INKT) director awarded 1,263 RSUs for board service

Rhea-AI Filing Summary

MiNK Therapeutics director reports new stock-based compensation. A company director received 1,263 restricted stock units (RSUs) of MiNK Therapeutics, Inc. common stock on 12/01/2025 at a value of $11.09 per share. These RSUs were granted in lieu of cash retainers for board and committee service and will vest one month after the grant date, at which point each RSU converts into one share of common stock. After this grant, the director beneficially owns 20,234 shares directly and 27,830 shares indirectly through an irrevocable trust established for the benefit of the director’s family.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

WIINBERG ULF

(Last) (First) (Middle)

149 FIFTH AVENUE, SUITE 500

(Street)

NEW YORK NY 10010

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
MiNK Therapeutics, Inc. [ INKT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
12/01/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	12/01/2025		A		1,263	A	$11.09(1)	20,234	D
Common Stock								27,830(2)	I	See Footnote(2)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Common Stock for each RSU. The RSUs were received in lieu of cash retainers for board and committee compensation. The RSUs will vest one month from the grant date.

2. Shares are held in an irrevocable trust for the benefit of Mr. Wiinberg's family.

	By: /s/ Christine Klaskin, Attorney-in-Fact	12/03/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did MiNK Therapeutics (INKT) report in this Form 4?

The filing reports that a director of MiNK Therapeutics, Inc. received 1,263 restricted stock units (RSUs) of common stock on 12/01/2025 as compensation.

At what price were the MiNK Therapeutics (INKT) RSUs valued in the Form 4?

The 1,263 RSUs were reported with a price of $11.09 per share, reflecting the value used for this grant of common stock-based compensation.

How and when do the reported RSUs for MiNK Therapeutics (INKT) vest?

The RSUs represent a right to receive one share of common stock per RSU and were granted in lieu of cash retainers. They will vest one month from the grant date of 12/01/2025.

How many MiNK Therapeutics (INKT) shares does the director own after this transaction?

Following the reported transaction, the director beneficially owns 20,234 shares of MiNK Therapeutics common stock directly and 27,830 shares indirectly through an irrevocable family trust.

Why did MiNK Therapeutics grant RSUs instead of cash to the director?

The filing states that the director’s RSUs were received in lieu of cash retainers for board and committee compensation, replacing cash payments with equity-based awards.

What is the nature of the indirect ownership reported for MiNK Therapeutics (INKT)?

The filing explains that the 27,830 indirectly owned shares are held in an irrevocable trust established for the benefit of the director’s family.